Vaccine
Ad26.COV2.S
Developer
Johnson & Johnson
Производитель
Johnson & Johnson
Status
Over the course of clinical trials by 44,000 volunteers from the United States, South Africa and Latin American countries, the vaccine demonstrated a 67% effectiveness rate.
The third phase of trials, which began in September 2020, will include 45,000 volunteers, with results expected by January. In November 2020, the company announced additional trials to evaluate the potential benefits of a second dose of the vaccine. After approval, total production of the vaccine is estimated to reach 1 billion doses per year, with worldwide availability.
Key information
What’s in the vaccine?
To create the Ad26.COV2.S vaccine, the tried-and-true Ad26 adenovirus vector was used. In the past, Johnson & Johnson employees used it to create vaccines against Ebola and other infections.
